Prosecution Insights
Last updated: November 04, 2026
Application No. 18/755,668

LASER ILLUMINATION DEVICE FOR TREATING PERIPHERAL ARTERIAL OCCLUSIVE DISEASE

Final Rejection §103
Filed
Jun 27, 2024
Priority
Jun 29, 2023 — provisional 63/510,891
Examiner
ROBLES, EILEEN
Art Unit
3792
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Ting-Ting Lam
OA Round
2 (Final)
100%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 100% — above average
100%
Career Allowance Rate
1 granted / 1 resolved
+30.0% vs TC avg
Minimal +0% lift
Without
With
+0.0%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 0m
Avg Prosecution
26 currently pending
Career history
29
Total Applications
across all art units

Statute-Specific Performance

§101
14.4%
-25.6% vs TC avg
§103
36.1%
-3.9% vs TC avg
§102
17.5%
-22.5% vs TC avg
§112
23.7%
-16.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment The amendment filed July 31, 2026 has been entered. Claims 1-3 and 5-10 remain pending in the application. Applicant’s amendments to the claims have overcome each and every prior objection and 112(b) rejections previously set forth in the Non-Final Office Action mailed April 2, 2026. More detailed provided below. Response to Arguments Claim objections: Applicant amended claims and addressed all previous claim objections and the objection have been withdrawn. 35 USC § 112: Applicant has cancelled claim 4, the previous 112(b) rejection have been withdrawn. Applicant has amended claim 6, the previous 112(b) rejection have been withdrawn. 35 USC § 103; Applicant's arguments filed 07/31/2026 have been fully considered but they are not persuasive. On pg. 5 of Applicant’s response, applicant argues that Belkowski does not teach a laser illumination device. As stated in the previous Non-Final Office Action, Belkowski teaches a light integration device comprising a plurality of LEDs but does not explicitly state using laser diodes for treating inflammatory conditions. However, Loupis teaches laser diodes (para. 0115). The incorporation of Loupis’ laser diodes to Belkowski’s device, provides a laser illumination device. Additionally, applicant argues that Belkowski does not treat peripheral occlusive disease. Applicant’s specification (para. 0002, 0057) lists foot ulcer as the most significant symptom of a peripheral arterial occlusive disease, as well as having poor blood circulation. Belkowski’s device is used to treat inflammatory conditions by increasing circulation (para. 0027) and Loupis’ device is used for treating ulcers (para. 0219). On pg.s 5-6 of Applicant’s response, applicant argues that Belkowski teaches laser sensors. However, as stated in the previous Non-Final Office Action, Examiner used the plurality of LEDs associated with the light panel to teach the plurality of diodes emitting different wavelengths (para. 0025-0026). As noted in Belkowski (para. 0074), the sensors associated with a light integrated device may be laser sensors. On pg.s 6-10 of Applicant’s response, applicant argues that Belkowski’s heat dissipation member does not protect against laser diodes, which is different from the plurality of LEDs. Belkowski teaches a heat dissipation module that manages temperature within the light panel, where the plurality of LEDs are accommodated (para. 0044). Loupis teaches laser diodes (para. 0115). It would have been obvious to incorporate the heat dissipation module taught by Belkowski to use within Loupis’ laser diodes. Doing so dissipates heat associated with the laser diodes within the device. On pg. 10 of Applicant’s response, applicant argues that Walker’s tripod is different from the tripod of the instant application. It is well known in the art that a tripod is composed of a stand with three legs, which is shown in Walker’s Figure 4A. Additionally, Walker’s tripod is supporting the light sources. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-3, 5, and 7-8 are rejected under 35 U.S.C. 103 as being unpatentable over Belkowski et al. (US 20230012300A1), hereinafter Belkowski, in view of Loupis et al. (US 20160016001A1), hereinafter Loupis, and in further view of Walker et al. (US 11229804B1), hereinafter Walker. Regarding claim 1, Belkowski teaches a laser illumination device (Fig. 1A, para. 0006 (light integrated device)) for treating a peripheral artery occlusive disease (para. 0027, (inflammatory conditions, tissue level, "increase circulation")), which comprises: a fixing frame (Fig. 1 para. 0026, (light panel), Fig. 3A, element 302A (clasp), combination of the panel and the clasp)), which includes a fixing member (Fig. 3A) and a bracket (Fig. 3A, element 302A (clasp)), the fixing member being disposed on a top of the bracket (Fig. 3A), wherein an area of an inner side of the fixing member is greater than 25 cm² (para. 0029 (height of 11.8 inches is 29.97 centimeters and width of 11 inches is 27.94 centimeters)) and t he inner side of the fixing member is disposed with a plurality of a first kind of diodes which are used to emit light with a wavelength between 620 and 700 nm (para. 0026 (LEDs, 600-750 nm, 630 nm)), and a wavelength between 900 and 1100 nm (para. 0025 (LEDs, 750-1000 nm, 850 nm)); a power source (para. 0052 (power source)), which is disposed on the fixing frame and is used to supply power to the plurality of the first kind and the second kind of diodes (para. 0052 (power source connected to LEDs), 0006 (processor causes LEDs to operate), 0092 (processor within the machine learning outputs light)); and the plurality of the first kind of diodes and the plurality of the second kind of diodes are used to emit laser light of different wavelengths (para. 0026 (plurality of LEDs, red light, near infrared light)) to irradiate an affected area of a patient (para. 0047 (tissue area)) suffering from the peripheral arterial occlusive disease ((para. 0027, (inflammatory conditions, tissue level, "increase circulation")). Belkowski does not teach a plurality of a first kind of diodes are laser diodes, a plurality of a second kind of diodes are laser diodes, and a tripod, which is disposed at a bottom of the bracket to support the fixing frame. However, Loupis teaches a laser illumination device (Fig. 1, element 100 (device for emitting light)) for treating a peripheral arterial occlusive disease (para. 0219 (ulcers), which comprises: a fixing frame (Fig. 1, element 108, para. 0144 (body)) which includes a fixing member and a bracket (Fig. 1, element 106, para. 0144 (head)), the fixing member being disposed on a top of the bracket (Fig. 1), and the inner side of the fixing member is disposed with a plurality of a first kind of laser diodes (para. 0115 (diode lasers)) which are used to emit laser light with a wavelength between 620 and 700 nm (para. 0049 (635-750 nm)), and a plurality of a second kind of laser diodes which are used to emit laser light with a wavelength between 900 and 1100 nm (para. 0153 (third set of LEDs, 800-1000 nm); the plurality of the first kind of laser diodes and the plurality of the second kind of laser diodes (para. 0115 (diode lasers)) are used to emit laser light of different wavelengths (para. 0053 (emit light from a plurality of light sources), to irradiate an affected area of a patient suffering from the peripheral arterial occlusive disease (para. 0095 (treatment area irradiated)). Loupis does not teach a tripod which is disposed at a bottom of the bracket to support the fixing frame. However, Walker teaches a tripod (Fig. 4A, col. 8, lines 59-61 (tripod supports the light sources), which is disposed at a bottom of the bracket to support the fixing frame (Fig. 4A, element 44 (mount)). Belkowski, Loupis, and Walker are considered to be analogous to the claimed invention because they are in the same field of light integrated devices for phototherapy. Therefore, it would have been obvious to someone of ordinary skill in the art before the effective filing date of the claimed invention to have modified Belkowski to incorporate the teachings of Loupis and provide a plurality of laser diodes emitting different wavelengths. Loupis discloses light sources capable of emitting light with characteristics corresponding to both light emitting diodes and diode lasers, thereby suggesting the interchangeability or supplementation of such light sources in Belkowski's device. Additionally, it would have been obvious to someone of ordinary skill in the art before the effective filing date of the claimed invention to have modified Belkowski to incorporate the teachings of Walker and provide a tripod for the laser illumination device. Belkowski teaches a base (Fig. 3A), while Walker teaches a tripod, it is well known in the art to use a tripod for a base. Regarding Claim 2, Belkowski (in view of Loupis and in further view of Walker) teaches a laser illumination device comprising the features of claim 1 as discussed above. Belkowski further discloses a heat dissipation member disposed outside the fixing member (para. 0044 (heat dissipation module in light panel, manages temperature of LEDs)) to dissipate heat generated by the plurality of laser diodes. Regarding Claim 3, Belkowski (in view of Loupis and in further view of Walker) teaches a laser illumination device comprising the features of claim 1 as discussed above. Belkowski further discloses wherein the number of each of the plurality of the first kind of laser diodes and the plurality of the second kind of laser diodes is at least 8 (para. 0006 (one or more LEDs), para 0038 (8 LEDs on each row)). Regarding Claim 5, Belkowski (in view of Loupis and in further view of Walker) teaches a laser illumination device comprising the features of claim 1 as discussed above. Belkowski further discloses wherein the inner side of the fixing member is in a planar or curved shape (para. 0028 (curved light panel)). Regarding Claim 7, Belkowski (in view of Loupis and in further view of Walker) teaches a laser illumination device comprising the features of claim 1 as discussed above. Belkowski further discloses wherein the power source is further connected to a timing device so that the power source automatically turns off at a set time (para. 0033 (light panel includes a timer configured to automatically shut-off light panel)). Regarding Claim 8, Belkowski (in view of Loupis and in further view of Walker) teaches a laser illumination device comprising the features of claim 1 as discussed above. Belkowski further discloses a programmable digital controller (para. 0077 (processor located at the device)) for controlling the power source (para. 0052 (power source connected to LEDs), 0006 (processor causes LEDs to operate), 0092 (processor within the machine learning outputs light)), ensuring that a light power density of the laser light emitted by the plurality of the first kind and the second kind of laser diodes (para. 0039 (irradiance of light)) on the patient's affected area (para. 0027 (emit light towards a subject)). Belkowski does not teach a light power density range from 8 to 200 mW/cm². Loupis teaches a laser illumination device (Fig. 1, element 100 (device for emitting light)), which further comprises a programmable digital controller (Fig. 1, element 114)) for controlling the power source (para. 0146 (powers on/off LEDs)), ensuring that a light power density of the laser light emitted by the plurality of the first kind and the second kind of laser diodes (para. 0105 (modulates the power density of the light)) on the patient's affected area ranges from 8 to 200 mW/cm² (para. 0013 (power density of the light, about 15 to 75 mW/cm²)). It would have been obvious to someone of ordinary skill in the art before the effective filing date of the claimed invention to have modified Belkowski to incorporate the teachings of Loupis and provide a light power density range for the plurality of laser diodes to the affected area of a patient. Doing so would ensure that the light power density is in the range to provide therapeutic effects, as well as prevents the patient from having tissue damage or discomfort due to possible overheating. Claim 6 is rejected under 35 U.S.C. 103 as being unpatentable over Belkowski, in view of Loupis, and in further view of Walker and Liu et al. (US 20130190845A1), hereinafter Liu. Regarding Claim 6, Belkowski (in view of Loupis and in further view of Walker) teaches a laser illumination device comprising the features of claim 1 as discussed above. Belkowski further discloses wherein the plurality of the first kind of laser diodes and the plurality of the second kind of laser diodes are respectively installed on the inner side of the fixing member in an interleaved manner (Fig. 1A, para. 0038 (arranged in a random pattern)). Belkowski (in view of Loupis and in further view of Walker) does not teach a maximum and a minimum light intensities on an irradiated area of a target surface are within ±30% of an average light intensity. Liu teaches a laser illumination device (abstract), wherein the plurality of the first kind of laser diodes (para. 0006 (one or more first LEDs that emit light primarily at a first wavelength)) and the plurality of the second kind of laser diodes (para. 0006 (one or more second LEDs that emit light primarily at a second wavelength)) are respectively installed on the inner side of the fixing member (para. 006 (positioned along a panel edge)) in an interleaved manner (para. 0083 (non- uniform spaced LEDs)), ensuring that a maximum and a minimum light intensities on an irradiated area of a target surface are within +30% of an average light intensity (para. 0012 (uniformity of light projection of +/- 30% over the area of the panel front surface), 0078 (light emitted from the LEDs enters into panel through edge)). Belkowski and Liu are both considered to be analogous to the claimed invention because they are in the same field of light integrated devices for phototherapy. Therefore, it would have been obvious to someone of ordinary skill in the art before the effective filing date of the claimed invention to have modified Belkowski to incorporate the teachings of Liu and provide an irradiated surface within +30% of an average light intensity. Doing so would promote the consistent therapeutic effectiveness and reduces overexposure or underexposure to the irradiated surface. Claim 9 is rejected under 35 U.S.C. 103 as being unpatentable over Belkowski, in view of Loupis, and in further view of Walker and Cassano et al. (US 20220323784A1), hereinafter Cassano. Regarding Claim 9, Belkowski (in view of Loupis and in further view of Walker) teaches a laser illumination device comprising the features of claim 1 as discussed above. Belkowski further discloses wherein the power source provides the power in an alternating manner (para. 0052 (power source connected to LEDs), 0006 (processor causes LEDs to operate), 0092 (processor within the machine learning outputs light)). Belkowski (in view of Loupis and in further view of Walker) does not teach a frequency range of 40 to 1000 Hz. Cassano teaches a laser illumination device (para. 0002 (device for photo biomodulation therapy)) wherein the power source (Fig. 1, element 200 (controller), para. 0065 (controller supplies power to light sources)), provides the power in an alternating manner (para. 0104 (controller controls power level and pulsed/continuous operation of light sources)) with an alternating frequency of 40 to 1000 Hz (para. 0047 (emit light in a frequency range, about 40 Hz), 0048 (about 1000 Hz), para. 0104 (an individual light source can be actuated in a pulsed or continuous mode independent of other light sources)). Belkowski and Cassano are both considered to be analogous to the claimed invention because they are in the same field of light integrated devices for phototherapy. Therefore, it would have been obvious to someone of ordinary skill in the art before the effective filing date of the claimed invention to have modified Belkowski to incorporate the teachings of Cassano and provide a power supply having an alternating frequency of 40 to 1000 Hz. Doing so would provide adjustment of the light sources to achieve a desired therapeutic effect. Similarly, selecting a frequency range optimized treatment efficiency and irradiation time. Claim 10 is rejected under 35 U.S.C. 103 as being unpatentable over Belkowski, in view of Loupis, and in further view of view of Walker and Herzog et al. (US 20230404667A1), hereinafter Herzog. Regarding Claim 10, Belkowski (in view of Loupis and in further view of Walker) teaches a laser illumination device comprising the features of claim 1 as discussed above. Belkowski further discloses temperature sensor (para. 0081 (temperature sensor)) installed on the fixing member for sensing a skin temperature of the patient (para. 0081 (body part temperature)). Belkowski (in view of Loupis and in further view of Walker) does not explicitly disclose that the temperature sensor is infrared. Herzog teaches a teaches an infrared temperature sensor (para. 0042 (infrared sensor)) installed on the fixing member for sensing a skin temperature of the patient (para. 0042 (measuring the temperature of the patient's skin)). Belkowski and Herzog are both considered to be analogous to the claimed invention because they are in the same field of laser skin treatment. Therefore, it would have been obvious to someone of ordinary skill in the art before the effective filing date of the claimed invention to have modified Belkowski to incorporate the teachings of Herzog and provide an infrared temperature sensor. Doing so would allow the sensor to reach the infrared ranges of the wavelengths, thereby providing patient safety to prevent overheating. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to EILEEN ROBLES whose telephone number is (571)429-9383. The examiner can normally be reached Monday-Friday: 8:00 - 5:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Niketa Patel can be reached at (571) 272-4156. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /EILEEN ROBLES/Examiner, Art Unit 3792 /William J Levicky/ Primary Examiner, Art Unit 3796
Read full office action

Prosecution Timeline

Jun 27, 2024
Application Filed
Apr 02, 2026
Non-Final Rejection mailed — §103
Jul 31, 2026
Response Filed
Aug 25, 2026
Final Rejection mailed — §103 (current)

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
100%
Grant Probability
99%
With Interview (+0.0%)
2y 0m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month